No Data
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
TD Cowen analyst Tyler Van Buren maintains $Artiva Biotherapeutics(ARTV.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 1.6%
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Wedbush Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $18
Wedbush analyst David Nierengarten maintains $Artiva Biotherapeutics(ARTV.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 45
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From Wedbush
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Needham analyst Gil Blum maintains $Artiva Biotherapeutics(ARTV.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 39.9% and
Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials
No Data
